Filament Health Corp.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FH.NE research report →
Companyfilament.health
Filament Health Corp. operates as a natural psychedelic drug discovery and extraction technology company. It propagates psychedelic plants; conducts genetic research; performs extraction procedures; runs in-house trials; and distributes IP and drug candidates to drug developers, researchers, and other licensed parties.
- CEO
- Benjamin Lightburn
- IPO
- 2021
- Employees
- 13
- HQ
- Burnaby, BC, CA
Price Chart
Valuation
- Market Cap
- $3.93M
- P/E
- -0.76
- P/S
- 8.75
- P/B
- 2.45
- EV/EBITDA
- -1.17
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 87.94%
- Op Margin
- -501.79%
- Net Margin
- -771.42%
- ROE
- -274.09%
- ROIC
- -142.56%
Growth & Income
- Revenue
- $616.68K · -71.06%
- Net Income
- $-4,970,000 · 6.61%
- EPS
- $-0.02 · 29.58%
- Op Income
- $-3,669,000
- FCF YoY
- 44.89%
Performance & Tape
- 52W High
- $0.07
- 52W Low
- $0.01
- 50D MA
- $0.02
- 200D MA
- $0.03
- Beta
- 0.72
- Avg Volume
- 4.89M
Get TickerSpark's AI analysis on FH.NE
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our FH.NE Coverage
We haven't published any research on FH.NE yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate FH.NE Report →